Pharmacy benefits are an important component within a Consumer Driven plan. There is no other benefit that offers as much impact on cost and delivers as much member control as pharmacy benefits. In fact, a consumer based pharmacy program, is an excellent start in a CDHP implementation strategy. Either offered along side a high deductible health plan, or as a stand-alone benefit with an HRA program, the ConsumerDrivenRx.com program will provide a solid foundation for any CDHP initiatives.

Pharmacy benefits have a great impact in a CDHP:

"Recent analyses of benefit design changes provide some insight into how CDHPs could affect patient utilization of drugs and other services. While most published studies have been too short to capture longer-term effects on health outcomes, most have documented both a shift in utilization toward lower-priced therapies1 (particularly generics)2 and an overall fall in use as patients have elected to forego prescribed medication3. "

"As expected, consumer-directed plans have shown positive results in motivating Generic drug use. It's an easy win as generic drugs are generally an underutilized alternative. The director of a top health benefit consultancy firm typically sees pharmacy spending drop by as much as 15% in the first year and attributes this entirely to a switch to generic medication. On large scale, this can result in a large cost savings for health plans - with important and potentially negative implications for the manufacturers of branded products.4 "

  1. Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids. J Manag Care Pharm. 2004;10(3):226-33.
  2. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH, Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2004;164(15):1679- 84.
  3. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-32.
  4. J Sheehan. The Consumer-Directed Health Market: Implications of New Benefit Designs 2006